7 July 2016
OGD2 Pharma and Green Cross LabCell start collaboration for developing NKcell therapeutics targeting the O-acetyl-GD2 cancer antigen
Nantes France & Seoul Korea, June 22, 2016 –
OGD2 Pharma SAS, a biotechnology company developing innovative anti-cancer therapies targeting the O-acetylated form of the GD2 ganglioside (OAcGD2), today announces a collaboration with Green Cross LabCell (GCLC), a subsidiary of Green Cross Corporation, a leading South Korean biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines.